Literature DB >> 17332931

Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis.

Yoichi Mizutani1, Hiroyuki Nakanishi, Yong Nan Li, Hiroki Matsubara, Kosuke Yamamoto, Nodoka Sato, Takumi Shiraishi, Terukazu Nakamura, Kazuya Mikami, Koji Okihara, Natsuki Takaha, Osamu Ukimura, Akihiro Kawauchi, Norio Nonomura, Benjamin Bonavida, Tsuneharu Miki.   

Abstract

X-linked inhibitor of apoptosis protein (XIAP) is the most potent caspase-inhibitory IAP family member and a negative regulator of various apoptotic stimuli. Thus, XIAP overexpression in cancer cells may select for tumor cell survival following various cytotoxic therapeutic modalities. The anatomical staging system in renal cell carcinoma (RCC) currently provides good prognostic information, albeit insufficient. We hypothesize that overexpression of XIAP in RCC may serve as a molecular prognostic marker in RCC and improve the staging of RCC. This study examined the protein level of XIAP in lysates from surgical specimens of 109 patients with RCC and 109 normal kidney specimens from the same patients. The level of XIAP expression was quantified by Western blot analysis using non-fixed fresh frozen tissues of RCCs and normal kidneys. Results indicated that the mean level of XIAP expression was higher in RCC compared to autologous normal kidney, and the XIAP expression level in 38/109 (35%) of RCC was more than 2-fold greater than that in normal kidney tissue. In Stage I/II RCC, the mean XIAP expression level was almost identical to that detected in normal kidney, whereas XIAP expression in Stage III/IV was 2.5-fold higher than that in Stage I/II RCC. Levels of XIAP expression also correlated with the grade of RCC. Patients with RCC with low XIAP expression had a longer postoperative disease-specific survival as compared to those with high expression in the 5-year follow-up. The suggested role of XIAP in the regulation of resistance in apoptosis was examined in vitro following treatment of RCC cell lines with XIAP antisense oligonucleotide and the cells were sensitized to both Fas-mediated and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. The present study demonstrates at the protein level that XIAP is overexpressed in RCC, and that high XIAP expression in RCC predicted a worse prognosis. In addition, XIAP antisense oligonucleotide sensitized RCC to Fas/TRAIL-induced apoptosis. These results suggest that XIAP expression in RCC may be used as a prognostic parameter, and that downregulation or inhibition of XIAP expression in RCC may reverse immune resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332931

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  55 in total

1.  Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder.

Authors:  A K Srivastava; P K Singh; D Singh; D Dalela; S K Rath; M M Goel; M L B Bhatt
Journal:  Tumour Biol       Date:  2014-05-23

2.  Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients.

Authors:  Ying-Chun Xu; Qiang Liu; Jia-Qi Dai; Zhi-Qiang Yin; Lei Tang; Yue Ma; Xiao-Lin Lin; Hong-Xia Wang
Journal:  Med Oncol       Date:  2014-01-21       Impact factor: 3.064

3.  Co-expression of XIAP and CIAP1 Play Synergistic Effect on Patient's Prognosis in Head and Neck Cancer.

Authors:  Xi-Hu Yang; Liu Liu; Yong-Jie Hu; Ping Zhang; Qin-Gang Hu
Journal:  Pathol Oncol Res       Date:  2018-11-12       Impact factor: 3.201

Review 4.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 5.  Targeting IAP proteins for therapeutic intervention in cancer.

Authors:  Simone Fulda; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

6.  Lack of prognostic significance of survivin in pediatric medulloblastoma.

Authors:  Roberta Soares Faccion; Regina Moreira Ferreira; Marília Fornaciari Grabois; Theresinha Carvalho Fonseca; Jose Antonio de Oliveira; Raquel Ciuvalschi Maia
Journal:  Pathol Oncol Res       Date:  2011-06-17       Impact factor: 3.201

7.  Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Sheng Zhou; Yuhong Du; Jing Xiong; Sha Yi; Cheng-Kui Qu; Haian Fu; Muxiang Zhou
Journal:  Cancer Cell       Date:  2016-09-22       Impact factor: 31.743

8.  Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

Authors:  Fiona M Foster; Thomas W Owens; Jolanta Tanianis-Hughes; Robert B Clarke; Keith Brennan; Nigel J Bundred; Charles H Streuli
Journal:  Breast Cancer Res       Date:  2009-06-29       Impact factor: 6.466

9.  Assessment of XAF1 as A Biomarker to Differentiate Hepatocellular Carcinoma from Nonneoplastic Liver Tissues.

Authors:  Ying Lin; Wei Li
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

10.  XIAP is not required for human tumor cell survival in the absence of an exogenous death signal.

Authors:  John Sensintaffar; Fiona L Scott; Robert Peach; Jeffrey H Hager
Journal:  BMC Cancer       Date:  2010-01-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.